Interventional News’ most popular stories from July included point of view pieces from interventional radiologists on fallopian tube recanalisation and interventions for postpartum haemorrhage, respectively; news of an editorial from The Cardiovascular Interventional Radiological Society of Europe (CIRSE) which takes a stance on paclitaxel-coated devices; and a report of a Society of Interventional Radiology (SIR) position statement offering recommendations on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents.
A French group of interventional radiologists and urologists has recently published the results of its randomised, multicentre, open-label, phase 3 superiority trial of prostate artery embolization (PAE) versus medical therapy (PARTEM) in The Lancet. The group, of whom Marc Sapoval (Hôpital Européen Georges Pompidou, Paris, France) is the corresponding author, states in its publication that the PARTEM trial met its primary endpoint
Alberto Alonso Burgos and Luis Chiva de Agustín (Universidad de Navarra, Pamplona, Spain) explain how where fertility is concerned, each woman is unique, and a one-size-fits-all approach is not appropriate for addressing what can be extremely complex reproductive health issues.
Biotronik has announced one-year subgroup results from the investigator-initiated BIOPACT randomised controlled trial (RCT), which were presented by principal investigator Koen Deloose (AZ Sint-Blasius, Dendermonde, Belgium) at this year’s Leipzig Interventional Course (LINC 2023, 6–9 June, Leipzig, Germany).
The SIR has published a position statement offering recommendations on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents. The statement, published online in the Journal of Vascular and Interventional Radiology, is a companion to the 2022 statement on the treatment of acute iliofemoral deep vein thrombosis.
Terumo Aortic has announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for commercial sale in Japan for the treatment of patients with complex aortic arch disease.
Following the news that the US Food and Drug Administration (FDA) has changed its stance on the use of paclitaxel-coated devices to treat peripheral arterial disease (PAD), Boston Scientific has announced its position on the update.
Endologix has shared in a press release that the first patients underwent percutaneous transmural arterial bypass (PTAB) using the Detour system since US FDA approval of the system was granted. This marks the official start of its US targeted market release.
In June 2023, CIRSE published an editorial in Cardiovascular Interventional Radiology (CVIR). Written on behalf of CIRSE’s Endovascular Subcommittee, the authors “advocate that the benefits of paclitaxel-coated device used in the femoropopliteal segment in terms of increased primary patency and reduced target lesion revascularisation warrant their use in the routine treatment of patients with femoropopliteal disease”.
Francis Medical has announced that the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapour ablation therapy for managing prostate cancer.
Lakshmi Ratnam (St George’s University Hospitals NHS Foundation Trust, London, UK) speaks about how the CIRSE 2020 Standards of Practice document for gynaecological and obstetric haemorrhage are among the most comprehensive guidelines in interventional radiology (IR) for obstetric interventions.